Suppr超能文献

[恶性淋巴瘤的新治疗方法——综述]

[New treatments of malignant lymphoma--a review].

作者信息

Mark Michael, Cerny Thomas

机构信息

Departement Innere Medizin, Onkologie/Hämatologie, Kantonsspital St. Gallen, St. Gallen.

出版信息

Ther Umsch. 2010 Oct;67(10):537-43. doi: 10.1024/0040-5930/a000090.

Abstract

For years chemotherapy regimens were the only possibility of treating malignant lymphoma. Although good responses could be achieved, a substantial proportion of patients are still not cured. Rituximab's development as an anti-CD20 antibody heralded a new era in treatment approaches for non-Hodgkin lymphomas (NHLs). The evolution of rituximab has led to intense interest in this type of therapeutic approach and to development and approval of the radioimmunoconjugates of rituximab and fully humanised antibodies. In recent years, the knowledge of the cellular and molecular biology of distinct types of NHLs have led to the development of a new class of drugs that specifically targets unique disease-specific pathways. Bendamustine and proteasome inhibitors are already approved in the treatment of individual entities of lymphoma. Histone deacetylase inhibitors, idiotype vaccination and other molecules show promising results in the lymphoma research that they are being verified in ongoing clinical trials.

摘要

多年来,化疗方案一直是治疗恶性淋巴瘤的唯一选择。尽管可以取得较好的疗效,但仍有相当一部分患者无法治愈。利妥昔单抗作为一种抗CD20抗体的研发开创了非霍奇金淋巴瘤(NHL)治疗方法的新纪元。利妥昔单抗的发展引发了人们对这类治疗方法的浓厚兴趣,并推动了利妥昔单抗放射性免疫缀合物和完全人源化抗体的研发与获批。近年来,对不同类型NHL细胞和分子生物学的认识促使了一类新型药物的开发,这类药物专门针对独特的疾病特异性途径。苯达莫司汀和蛋白酶体抑制剂已被批准用于治疗个别类型的淋巴瘤。组蛋白去乙酰化酶抑制剂、独特型疫苗接种及其他分子在淋巴瘤研究中显示出了有前景的结果,目前正在进行的临床试验中对其进行验证。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验